17th Aug 2017 09:00
For immediate release | 17 August 2017 |
Quantum Pharma Plc
('Quantum' or the 'Company')
Notice of Interim Results: Date Change
Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier, announces that the Company will publish its unaudited interim results for the half year ended 31 July 2017 on Tuesday 22 August 2017.
A conference call for analysts will be held at 9.30 am on the day of the results; for analysts wishing to join the conference call, please contact Buchanan on 020 7466 5000 or email [email protected].
- Ends -
For further information: Quantum Pharma Plc |
| ||
Chris Rigg, Chief Executive Officer | Tel: +44 (0) 1207 279 404 | ||
Gerard Murray, Chief Financial Officer | www.quantumpharmaplc.com | ||
| |||
N+1 Singer |
|
| |
(Nominated Advisor & Broker) |
|
| |
Sandy Fraser / Nick Owen / James White | Tel: +44 (0) 20 7496 3000 |
| |
Media enquiries: Buchanan |
| ||
Henry Harrison-Topham / Sophie Cowles | Tel: +44 (0) 20 7466 5000 | ||
www.buchanan.uk.com |
| ||
Notes to Editors
Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesale and hospital markets. Quantum Pharma Plc operates through two divisions - Specials and Niche Pharmaceuticals - offering a portfolio of innovative and complementary products and services.
For further information, please visit www.quantumpharmagroup.com.
Related Shares:
Quantum Pharma